The NHS will not offer a drug that gives patients with advanced breast cancer a last hope because it is too expensive.
Women with HER2-positive breast cancer, which has spread to other parts of their body and has not responded to initial treatment, can see their lives extended by around six months by Kadcyla.
However, the National Institute for Health and Care Excellence (Nice) has ruled that at around £90,000 per patient, the drug is too expensive to recommend for widespread use in the health service.
The NHS financial watchdog criticised Roche, who manufactures the drug, for not discounting the treatment further.
Roche said that is had offered to cut the price of the drug and will be appealing Nice's decision.
More top news
Former shadow chancellor Ed Balls has revealed he turned down an offer to go on ITV reality show I'm A Celebrity... Get Me Out of Here!
Crowds have gathered for the first "blue moon" since 2012 and the last until 2018.
A 21-year-old man who is paralysed from the neck down can walk again thanks to a mind-controlled robotic skeleton.